Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
- PMID: 38179623
- PMCID: PMC10905658
- DOI: 10.2807/1560-7917.ES.2024.29.1.2300703
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
Abstract
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6-74.3), VE against ICU admission was 73.3% (95% CI: 42.2-87.6).
Keywords: COVID-19; COVID-19 vaccination; Vaccine effectiveness.
Conflict of interest statement
Figures


Similar articles
-
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25. Lancet Respir Med. 2023. PMID: 37898148
-
Informed consent for national registration of COVID-19 vaccination caused information bias of vaccine effectiveness estimates mostly in older adults: a bias correction study.J Clin Epidemiol. 2024 Oct;174:111471. doi: 10.1016/j.jclinepi.2024.111471. Epub 2024 Jul 18. J Clin Epidemiol. 2024. PMID: 39032589
-
Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.Influenza Other Respir Viruses. 2024 Aug;18(8):e13360. doi: 10.1111/irv.13360. Influenza Other Respir Viruses. 2024. PMID: 39145535 Free PMC article.
-
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36730051 Free PMC article.
-
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.Int J Infect Dis. 2022 Jan;114:252-260. doi: 10.1016/j.ijid.2021.11.009. Epub 2021 Nov 17. Int J Infect Dis. 2022. PMID: 34800687 Free PMC article. Review.
Cited by
-
Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages.Open Forum Infect Dis. 2024 Jul 1;11(7):ofae370. doi: 10.1093/ofid/ofae370. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39015348 Free PMC article.
-
Biases in COVID-19 vaccine effectiveness studies using cohort design.Front Med (Lausanne). 2024 Oct 30;11:1474045. doi: 10.3389/fmed.2024.1474045. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39540039 Free PMC article. Review.
-
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.Vaccines (Basel). 2024 Jul 2;12(7):734. doi: 10.3390/vaccines12070734. Vaccines (Basel). 2024. PMID: 39066372 Free PMC article.
-
COVID-19 vaccine effectiveness against SARS-CoV-2-confirmed hospitalisation in the eastern part of the WHO European Region (2022-2023): a test-negative case-control study from the EuroSAVE network.Lancet Reg Health Eur. 2024 Oct 22;47:101095. doi: 10.1016/j.lanepe.2024.101095. eCollection 2024 Dec. Lancet Reg Health Eur. 2024. PMID: 39726724 Free PMC article.
-
Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.bioRxiv [Preprint]. 2024 Apr 6:2024.04.05.588359. doi: 10.1101/2024.04.05.588359. bioRxiv. 2024. PMID: 38712124 Free PMC article. Preprint.
References
-
- National Institute for Public Health and the Environment (RIVM). Deelname COVID-19-vaccinatie in Nederland (19 december 2023) [Uptake of COVID-19 vaccination in the Netherlands (19 December 2023)]. Bilthoven: RIVM; 2023. [Dutch]. Available from: https://www.rivm.nl/corona/actueel/vaccinatiecijfers/update-deelname-cov...
-
- Government of the Netherlands. Coronavirus Dashboard. Virus particles in wastewater. The Hague: Rijksoverheid. [Accessed: 20 Dec 2023]. Available from: https://coronadashboard.government.nl/landelijk/rioolwater
-
- Government of the Netherlands. Coronavirus Dashboard. View on the hospitals. The Hague: Rijksoverheid. [Accessed: 12 Dec 2023]. Available from: https://coronadashboard.government.nl/landelijk/ziekenhuizen-in-beeld
-
- Van Werkhoven CH, De Gier B, McDonald SA, De Melker HE, Hahne SJM, Van den Hof S, et al. Information bias of vaccine effectiveness estimation due to informed consent for national registration of COVID-19 vaccination: estimation and correction using a data augmentation model. medRxiv. 2023:2023.05.23.23290384 .10.1101/2023.05.23.23290384 - DOI
-
- National Institute for Public Health and the Environment (RIVM). Uitvoeringsrichtlijn COVID-19-vaccinatie, versie 5.1 (8 december 2023). [COVID-19 guideline version 5.1 (8 December 2023)]. Bilthoven: RIVM; 2023. Dutch. Available from: https://lci.rivm.nl/richtlijnen/covid-19-vaccinatie
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical